Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and energy, preventing protein catabolism and ketosis. Sodium chloride maintains osmotic pressure and fluid balance. Potassium chloride replenishes potassium and maintains intracellular ion gradients.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
FDA: Source of water, electrolytes, and calories for parenteral nutrition when oral intake is not possible,Off-label: Treatment of hypokalemia, maintenance fluid therapy
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric needs. Typical adult maintenance: 100-125 m L/hour (2-3 L/day) of D5 0.2% Na Cl with 0.15% KCl (20 m Eq KCl/L) administered via continuous IV infusion.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: Not applicable (endogenous substrate, rapidly cleared via metabolism). Potassium: Terminal elimination half-life ~12-24 hours in healthy individuals, prolonged in renal impairment. Sodium and chloride: No defined half-life; renal excretion is regulated by homeostatic mechanisms.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the Krebs cycle. Sodium chloride and potassium chloride are not metabolized; they are excreted primarily by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: Dextrose is completely metabolized to CO2 and water; only trace amounts excreted unchanged (<2%). Sodium and chloride are primarily excreted renally, with >90% of filtered load reabsorbed; excess is excreted in urine. Potassium is predominantly excreted renally (90%), with minor fecal (10%) loss. Biliary excretion is negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: Negligible (<1%). Sodium: Negligible. Chloride: Negligible. Potassium: Negligible. No specific binding proteins.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: 0.2-0.3 L/kg (mainly extracellular fluid). Sodium: 0.6-0.7 L/kg (total body water). Chloride: 0.4-0.5 L/kg (extracellular fluid). Potassium: 3-5 L/kg (primarily intracellular; Vd large due to active transport into cells).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%. Oral: Not applicable (solution is for IV use only).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR <30 m L/min: use with caution; reduce potassium content as needed based on serum potassium levels; avoid if anuria or severe renal impairment. No specific dose adjustment for the dextrose/saline component, but consider total volume and electrolyte content.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: no adjustment. Class B or C: monitor serum potassium and glucose; consider reducing potassium if hyperkalemia risk; no specific dose change required but infusion rate may need adjustment based on fluid tolerance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based: 0.2% Na Cl with 0.15% KCl in 5% dextrose. Rate: 100-150 m L/kg/day for maintenance; adjust based on age, weight, and clinical condition. Potassium: 1-2 m Eq/kg/day, not to exceed 3 m Eq/kg/day. Administer via IV infusion.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: use with caution due to potential renal impairment and reduced cardiac reserve. Monitor serum potassium and renal function closely. Infusion rates should be conservative, generally lower than younger adults, with careful attention to fluid balance to avoid overload.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with anuria. Potassium-containing solutions should not be used in patients with severe renal impairment or hyperkalemia.
None.
Monitor serum electrolytes, including potassium and sodium, and blood glucose levels,Risk of hyperkalemia, especially in patients with renal impairment or those receiving potassium-sparing diuretics,Avoid fluid overload in patients with heart failure or renal impairment,Use with caution in patients with diabetes mellitus or glucose intolerance
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Severe renal impairment (anuria or oliguria),Addison's disease,Severe burns or trauma,Solutions containing dextrose may be contraindicated in patients with known allergy to corn
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, patients with renal impairment may require dietary potassium and sodium restrictions. Avoid high-potassium foods if hyperkalemia is a concern.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological doses. Inadvertent excessive administration leading to electrolyte imbalances may pose indirect fetal risks (e.g., hyperkalemia causing fetal arrhythmias). Use during pregnancy only if clearly needed and with monitoring.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose, sodium, and potassium are normal constituents of breast milk. IV administration at standard doses does not significantly alter milk composition. M/P ratio not applicable; use during lactation is considered safe.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment required for pregnancy-related pharmacokinetic changes; standard dosing based on clinical need and electrolyte monitoring.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Avoid in severe hyperkalemia, hypernatremia, or fluid overload. Use cautiously in patients with renal impairment or heart failure. Monitor serum potassium and glucose levels during prolonged infusion. Do not administer via same line as blood products due to risk of hemolysis.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inform your healthcare provider if you have a history of heart failure, kidney disease, or diabetes.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,Do not adjust the infusion rate yourself; it is set by the healthcare professional.,Tell your doctor if you are pregnant or breastfeeding.,This solution contains potassium; do not take extra potassium supplements without consulting your doctor.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and energy, preventing protein catabolism and ketosis. Sodium chloride maintains osmotic pressure and fluid balance. Potassium chloride replenishes potassium and maintains intracellular ion gradients.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric needs. Typical adult maintenance: 100-125 m L/hour (2-3 L/day) of D5 0.2% Na Cl with 0.15% KCl (20 m Eq KCl/L) administered via continuous IV infusion.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological doses. Inadvertent excessive administra. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.